Cargando…

MET/PKCß expression correlate with metastasis and inhibition is synergistic in lung cancer

BACKGROUND: Treatment of non-small cell lung cancer (NSCLC) remains a difficult task in oncology. Targeted inhibition of oncogenic proteins is promising. In this study, we evaluate the expression of MET and PKCß and in vitro effects of their inhibition using SU11274 and enzastaurin (LY317615.HCl) re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faoro, Leonardo, Cervantes, Gustavo M., Ferguson, Benjamin D., Seiwert, Tanguy Y., Yala, Soheil, Vigneswaran, Wicki T., Westerhoff, Maria, Tretiakova, Maria S., Ferguson, Mark K., Moura, Glaci L., Husain, Aliya N., Vokes, Everett E., Salgia, Ravi
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791827/ https://www.ncbi.nlm.nih.gov/pubmed/19955662 http://dx.doi.org/10.4103/1477-3163.57857

Ejemplares similares

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer
por: Kanteti, Rajani, et al.
Publicado: (2014)

Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism
por: Loganathan, Sivakumar, et al.
Publicado: (2011)

MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2014)

The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target
por: Ferguson, Benjamin D., et al.
Publicado: (2013)

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma
por: Rolle, Cleo E., et al.
Publicado: (2016)

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
por: Tan, Yi-Hung Carol, et al.
Publicado: (2017)

Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
por: Ma, P C, et al.
Publicado: (2007)

O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer
por: Hasina, Rifat, et al.
Publicado: (2013)

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
por: Surati, Mosmi, et al.
Publicado: (2011)

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation
por: Vigneswaran, Janani, et al.
Publicado: (2016)

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients
por: Poroyko, Valeriy, et al.
Publicado: (2018)

Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: Relevance to lung cancer
por: Kawada, Ichiro, et al.
Publicado: (2013)

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database
por: Surati, Mosmi, et al.
Publicado: (2011)

CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2010)

Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer
por: Ren, Lili, et al.
Publicado: (2017)

Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer
por: Ferguson, Benjamin D., et al.
Publicado: (2015)

Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease
por: Mackinnon, Alexander C, et al.
Publicado: (2010)

Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma
por: Carey, George B, et al.
Publicado: (2012)

Correction: CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2011)

AB012. Automated histologic subtyping of thymic epithelial tumors with deep learning
por: Dolezal, James M., et al.
Publicado: (2022)

Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma
por: Ren, Lili, et al.
Publicado: (2019)

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies
por: Pederson, Aaron W, et al.
Publicado: (2011)

Pulmonary Parenchymal Changes in COVID-19 Survivors
por: Diaz, Ashley, et al.
Publicado: (2022)

AKT-ions with a TWIST between EMT and MET
por: Tang, Huifang, et al.
Publicado: (2016)

Heuristic value-based framework for lung cancer decision-making
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Molecular targeted therapies in head and neck cancer - An update of recent developements -
por: Goerner, Martin, et al.
Publicado: (2010)

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
por: Puri, Neelu, et al.
Publicado: (2008)

Tumor volume is an independent predictor of survival in patients with malignant pleural mesothelioma
por: Kircheva, Diana Y, et al.
Publicado: (2015)

DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer
por: Seiwert, Tanguy Y., et al.
Publicado: (2014)

PAX3 and ETS1 synergistically activate MET expression in melanoma cells
por: Kubic, Jennifer D., et al.
Publicado: (2014)

Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma
por: Lennon, Frances E., et al.
Publicado: (2016)

What’s new in kidney tumor pathology 2022: WHO 5th edition updates
por: Tretiakova, Maria
Publicado: (2022)

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2023)

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2016)

Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report
por: Roth, Katherine G., et al.
Publicado: (2020)

Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
por: Jiang, Xiufeng, et al.
Publicado: (2015)

Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma
por: Wei, Kai, et al.
Publicado: (2019)

EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma
por: Tan, Yi-Hung Carol, et al.
Publicado: (2019)

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer
por: Camidge, D. Ross, et al.
Publicado: (2023)

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Seiwert, Tanguy, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_63hpgqfbm9hnpj29eofp6lbb60